Abstract | OBJECTIVES: METHODS: Gram-negative isolates (4498 total: 2171 Pseudomonas species; 1910 Enterobacteriaceae; and 417 other Gram-negative bacilli) were collected from 80 centres in 16 countries in Europe, the Middle East and Africa during 2008-09. The MICs of doripenem, imipenem and meropenem were determined using Etest methodology and broth microdilution. Susceptibility was interpreted according to CLSI, EUCAST and FDA breakpoints. RESULTS: The MIC(90)s of doripenem, imipenem and meropenem for all isolates were 8, ≥64 and 32 mg/L, respectively. Doripenem had the lowest MIC(90) for Pseudomonas species at 16 mg/L, with imipenem and meropenem values of ≥64 mg/L. Enterobacteriaceae were highly susceptible to all three carbapenems, with MIC(90)s of doripenem, imipenem and meropenem of 0.06, 0.5 and 0.12 mg/L, respectively. Other Gram-negative isolates, predominantly Acinetobacter baumannii, were resistant to all three carbapenems (MIC(90) ≥64 mg/L). Susceptibility to doripenem was observed in 14.9% of isolates resistant to imipenem and/or meropenem. CONCLUSIONS:
|
Authors | Patrice Nordmann, Juan J Picazo, Reinier Mutters, Volkan Korten, Alvaro Quintana, Joerg M Laeuffer, Joyce Chen Hian Seak, Robert K Flamm, Ian Morrissey, COMPACT study group |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 66
Issue 5
Pg. 1070-8
(May 2011)
ISSN: 1460-2091 [Electronic] England |
PMID | 21393160
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Carbapenems
- Thienamycins
- Imipenem
- Doripenem
- Meropenem
|
Topics |
- Africa
- Anti-Bacterial Agents
(pharmacology)
- Carbapenems
(pharmacology)
- Cross Infection
(microbiology)
- Doripenem
- Europe
- Gram-Negative Bacteria
(drug effects, isolation & purification)
- Gram-Negative Bacterial Infections
(microbiology)
- Humans
- Imipenem
(pharmacology)
- Meropenem
- Microbial Sensitivity Tests
- Middle East
- Thienamycins
(pharmacology)
|